We hypothesize that, along with the previously discussed elevated frequencies of CD19 positive EVs in ALL and CLL, down regulated frequencies of CD19 positive EVs from AML and healthy serum samples might indicate tumor progression and an attenuated immune response. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.